Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04506749
Other study ID # UCAMCFE-00015
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 11, 2019
Est. completion date September 18, 2020

Study information

Verified date July 2020
Source Universidad Católica San Antonio de Murcia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single-blind, double-blind, controlled, randomized clinical trial of two parallel branches depending on the product consumed (experimental product and placebo product) and single-center with the objective of evaluating the effect of the investigational product on cardiovascular risk reduction.


Description:

Subjects who meet the selection criteria will make a total of two visits to the research laboratory and will carry out the tests established in the protocol. Subsequently, a statistical analysis will be performed with the variables measured in the study to obtain results.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date September 18, 2020
Est. primary completion date August 14, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Subjects of both sexes (men or women) between 30 and 75 years of age, Caucasian.

- Present body mass index between 20 and 32 Kg / m2.

- Presenting fasting serum LDL-cholesterol levels equal to or greater than 110 mg / dL or total serum cholesterol equal to or greater than 180 mg / dL.

- Volunteers capable of understanding the clinical study and willing to grant written informed consent and to comply with study procedures and requirements.

Exclusion Criteria:

- Thyroid dysfunction, infections, or with any type of chronic disease (eg, autoimmune, inflammatory).

- Subjects who have suffered an ischemic-vascular event in the last months.

- Subjects in medication and / or nutraceutical treatment for hypertension, diabetes or hyperlipidemia (ex: statins).

- Subjects in treatment with drugs that due to their narrow therapeutic margin require monitoring of their plasma levels (digoxin, acenocoumarol, warfarin, etc ...).

- Subjects in treatment that affects body weight or appetite.

- History of allergic hypersensitivity or poor tolerance to any component of the products under study.

- Subjects who are carrying out or intend to carry out any type of diet, low-calorie or not, during the study.

- Subjects who have donated a minimum of 0.5L of blood in the last month Vegetarian subjects.

- Subjects who have ingested omega 3 and / or 6 supplements in the last three months, (eg, fish oil, evening primrose oil, krill oil, or algae oil).

- Subjects under treatment with niacin or fibrates.

- Those subjects with alcohol abuse, or with excessive alcohol consumption (> 3 glasses of wine or beer / day) were excluded.

- Patients undergoing major surgery in the last 3 months.

- Smoking subjects or not, but in any case who have changed their nicotinic habits during their participation in the study.

- Participation in another clinical trial in the three months prior to the study.

- Lack of will or inability to comply with clinical trial procedures.

- Subjects whose condition did not make them eligible for the study according to the researcher's criteria.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Dietary supplement consumption
The consumption time was 56 days. Consumed 100 grams daily to consume during the day.

Locations

Country Name City State
Spain Catholic University of Murcia Murcia

Sponsors (1)

Lead Sponsor Collaborator
Universidad Católica San Antonio de Murcia

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Cholesterol Lipidic profile, measured in mg/dl It is measured on an empty stomach, change after 56 days of consumption.
Primary LDL - Cholesterol Lipidic profile, measured in mg/dl It is measured on an empty stomach, change after 56 days of consumption.
Primary HDL - Cholesterol Lipidic profile, measured in mg/dl It is measured on an empty stomach, change after 56 days of consumption.
Primary Triglycerides Lipidic profile, measured in mg/dl It is measured on an empty stomach, change after 56 days of consumption.
Secondary Assessing a change of blood pressure blood pressure is measured with a holter Blood pressure measurements will be taken with a Holter monitor on two separate occasions and for 24 hours each day. Measurements were made at baseline and after 56 days of product consumption. Systolic and diastolic blood pressure will be measured
Secondary Blood glucose Glycidic analysis, measured in mg/dL It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary Glycosylated hemoglobin (HBA1c) Glycidic analysis, measured in % It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary malondialdehyde (MDA) oxidative damage, measured in ng/ml It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary Oxidized LDL oxidative damage, measured in pg/mL It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary Superoxide Dismutase (SOD) antioxidant defense, measured in pg/mL It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary Interleukin-6 (IL-6) Inflammation, measured in pg/mL It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary Proteins C Reactive (PCR) Inflammation, measured in mg/l It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary Fat mass Bioimpedance, in Kg. It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary Muscle mass Bioimpedance, in Kg. It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary Body mass index Bioimpedance, in Kg/m2. It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary Percentage of fat mass Bioimpedance, in %. It is measured on an empty stomach, before and after the consumption time (56 days).
Secondary Control of dietary intake Diet source A nutritional registry will be carried out. The nutritional intake of three days in two periods will be collected. One record at the beginning and another at the end, that is, six days.
Secondary Physical Activity Questionnaire Measured with the questionnaire Global Questionnaire on Physical Activity It is measured before and after the consumption time (56 days).
Secondary Liver safety variables It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L) It is measured on an empty stomach, before and after the consumption time (56 days).
See also
  Status Clinical Trial Phase
Completed NCT01139827 - Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography N/A
Recruiting NCT05767073 - LIVES: Personalized Lifestyle Intervention for Patients With Depression N/A
Completed NCT04626505 - Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. Phase 2
Completed NCT00856882 - The Effects of Soy Protein and Isoflavones on Glycemic Control, Insulin Sensitivity and Cardiovascular Risk Factors N/A
Completed NCT04330937 - Clinical Trial on the Effectiveness of Citrolive N/A
Completed NCT01781416 - Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk N/A
Completed NCT01475513 - Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women Phase 4
Enrolling by invitation NCT06122961 - Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
Completed NCT03412175 - CREATION Health Lifestyle Intervention N/A
Completed NCT02144922 - Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients Phase 4
Completed NCT00921752 - C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS) N/A
Completed NCT00697580 - Strength and Nutrition Outcomes for Latino Adolescents N/A
Enrolling by invitation NCT04450914 - Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP) N/A
Completed NCT01003574 - Evaluation of Cardiovascular Health Outcomes Among Survivors N/A
Not yet recruiting NCT06118281 - ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack Phase 3
Completed NCT01441323 - Strength Training and Nutrition Development for African American Youth N/A
Completed NCT01103648 - Effect of Simvastatin and Ezetimibe on Lipid and Inflammation N/A
Completed NCT01015092 - Cardiovascular Risk Evaluation and Antiretrovirals in HIV N/A
Not yet recruiting NCT05882266 - The Role of Plant-Based Omega-3 Fatty Acids and Molecular Characterisation in Individuals With Cardiovascular(CVD) Risk N/A
Completed NCT00988754 - School Based Health Promotion Program in Secondary Schools N/A